This site is intended for patients who have been prescribed Remicade (infliximab). If you are a Healthcare Professional then please visit the HCP site, or if you are a member of the public please visit our public site. This site is not a substitute for the Patient Information Leaflet (PIL). The information provided is general education information and does not take place of professional medical advice.
This site is intended for adult patients who have been prescribed Remicade (infliximab). If you are a teen who has been prescribed Remicade (infliximab), please visit the Teens patient site. If you are a Healthcare Professional please visit the HCP site, or if you are a member of the public please visit our public site. This site is not a substitute for the Patient Information Leaflet (PIL). The information provided is general education information and does not take place of professional medical advice.
This page is intended for adolescent patients who have been prescribed Remicade (infliximab). If you are an adult who has been prescribed Remicade (infliximab), please visit the adults patient site. If you are a Healthcare Professional please visit the HCP site, or if you a member of the public please visit our public site. This site is not a substitute for the Patient Information Leaflet (PIL). The information provided is general education information and does not take the place of professional medical advice.
Hello
This website is intended for patients who have been prescribed Remicade (infliximab).
Access the content intended for you by clicking on the appropriate button below.
Disclaimer
Links to external sites
The link you have selected will take you to a third-party website. We do not review or control the content of any third-party site. We do not endorse and are not responsible for the accuracy, content, practices, or standards of any third-party sources.
References
- Kanai T et al. Korean J Intern Med 2014; 29(4): 409-15
- Olendzki BC et al. Nutr J 2014; 13(5): 1-7.
- Brown AC et al. Expert Rev. Gastroenterol. Hepatol 2011; 5(3): 411-25
- Pituch-Zdanowksa A et al. Prz Gastroenterol 2015; 10(3): 135-41.
- Oliviero F et al. Swiss Med Wkly 2015; 145: w14190.
- Clinton CM et al. Arthritis 2015; 2015: Article ID 708152.
- Narula N, Fedorak RN. Can J Gastroenterol 2008; 22 (5): 497-504
- Bilski J et al. BioMed Res Int 2014; Volume 2014 (Article ID 429031): 1-14.
- Benatti FB, Pedersen BK. Nat Rev Rheumatol 2015; 11: 86-97
- Nolte K et al. S Afr Fam Pract 2013; 55: 345-9
- Metsios GA et al. Expert Rev Clin Immunol 2015 [Epub ahead of print]
- Brophy S et al. Semin Arthritis Rheum 2013; 42: 619-26
Contact
For further information about Remicade (infliximab) please contact our Medical Information Department at:
Medical Information Department
Merck Sharp & Dohme (UK) Limited.
Registered Office: 120 Moorgate
London
EC2M 6UR
United Kingdom
Tel: 01992 467272
E-mail: medicalinformationuk@msd.com